OncoMatch/Clinical Trials/NCT06014905
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Is NCT06014905 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Hyperpolarized carbon C 13 pyruvate for meningioma.
Treatment: Hyperpolarized carbon C 13 pyruvate — This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
creatinine < 1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify